Arnedos M, Bihan C, Delaloge S, Andre F (2012) Triple-negative breast cancer: are we making headway at least? Ther Adv Med Oncol 4:195–210

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stratégie décennale de lutte contre les cancers 2021–2030, 2e rapport au président de la République / Institut National du Cancer. Mai 2023. https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Strategie-decennale-de-lutte-contre-les-cancers-2021-2030-deuxieme-rapport-au-president-de-la-Republique

Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA et al (2023) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 41:1809–1815

Article  CAS  Google Scholar 

Référentiel régional de prise en charge du cancer du sein, issu des travaux du groupe de professionnels du Nord et du Pas-de-Calais, Juin 2018. https://www.onco-hdf.fr/app/uploads/2019/05/Version-finale-s%C3%A9nologie.pdf

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S et al (2022) Event-free survival with Pembrolizumab in early triple-negative breast cancer. N Engl J Med 386:556–567

Article  CAS  PubMed  Google Scholar 

Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382:810–821

Article  CAS  PubMed  Google Scholar 

Dent RA, Cortès J, Pusztai L, McArthur HL, Kuellel S, Bergh J, and al. (2022). HRQoL with neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522. Annals of Oncology. 33: S600-S601.

Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18:e143–e152

Article  PubMed  PubMed Central  Google Scholar 

Nederlof I, Isaeva O, Bakker N, Graaf M, Salgado RF, Klioueva N, Vijver K, van Duijnhoven F, Kalashnikova E, Willingham S et al (2022) LBA13 Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial. Ann Oncol 33:S1382

Article  Google Scholar 

Ramtohul T, Tescher C, Vaflard P, Cyrta J, Girard N, Malhaire C et al (2022) Prospective evaluation of ultrafast breast MRI for predicting pathologic response after neoadjuvant therapies. Radiology 305:565–574

Article  PubMed  Google Scholar 

Kim JH, Park VY, Shin HJ, Kim MJ, Yoon JH (2022) Ultrafast dynamic contrast-enhanced breast MRI: association with pathologic complete response in neoadjuvant treatment of breast cancer. Eur Radiol 32:4823–4833

Article  CAS  PubMed  Google Scholar 

Tang WJ, Chen SY, Hu WK, Li XL, Zheng BJ, Wang ZS et al (2023) Abbreviated versus full-protocol MRI for breast cancer neoadjuvant chemotherapy response assessment: diagnostic performance by general and breast radiologists. AJR Am J Roentgenol 220:817–825

Article  PubMed  Google Scholar 

Avis final ANSM AP Keytruda 22.02.2022. https://ansm.sante.fr/actualites/avis-de-lansm-du-22-02-2022-sur-le-medicament-keytruda-25-mg-ml-solution-a-diluer-pour-perfusion-dans-le-cadre-dune-demande-daap

Cao Y, Wang X, Li L, Shi J, Zeng X, Huang Y et al (2023) Early prediction of pathologic complete response of breast cancer after neoadjuvant chemotherapy using longitudinal ultrafast dynamic contrast-enhanced MRI. Diagn Interv Imaging 104:605–614

Article  PubMed  Google Scholar 

Kataoka M (2023) Ultrafast DCE-MRI as a new tool for treatment response prediction in neoadjuvant chemotherapy of breast cancer. Diagn Interv Imaging 104:565–566

Article  PubMed  Google Scholar 

Mann RM, Mus RD, van Zelst J, Geppert C, Karssemeijer N, Platel B (2014) A novel approach to contrast-enhanced breast magnetic resonance imaging for screening : high-resolution ultrafast dynamic imaging. Invest Radiol 49:579–585

Article  PubMed  Google Scholar 

Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414–4422

Article  PubMed  Google Scholar 

Brierley JD, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours (ed.8), Wiley Blackwell, Oxford, UK 2017

Li H, Yao L, Jin P, Hu L, Li X, Guo T, Yang K (2018) MRI and PET/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer : a systematic review and meta-analysis. Breast 40:106–115

Article  PubMed  Google Scholar 

Vertakova Krakovska and L. Vanovcanova. Immunotherapy in Neoadjuvant Treatment of triple-negative breast cancer: First Insights and Treatment Monitoring with MI - Single Institution Retrospective Analysis